Is there discrimination in access to therapy for HCV patients?

n/

Ethics in clinical research

n/

Maggiore ricerca per i farmaci generici

n/

Il fine della ricerca indipendente: Non registrativa o registrativa

n/

Accelerating Prototype-Based Drug Discovery using Conditional Diversity Networks

Designing a new drug is a lengthy and expensive process. As the space of potential molecules is very large (10^23-10^60), a common technique during drug discovery is to start from a molecule which already has some of the desired properties. An interdisciplinary team of scientists generates hypothesis about the required changes to the prototype. In this work, we develop an algorithmic unsupervised-approach that automatically generates potential drug molecules given a prototype drug. We show that the molecules generated by the system are valid molecules and significantly different from the prototype drug. Out of the compounds generated by the system, we identified 35 FDA-approved drugs. As an example, our system generated Isoniazid - one of the main drugs for Tuberculosis. The system is currently being deployed for use in collaboration with pharmaceutical companies to further analyze the additional generated molecules

Il futuro della medicina

In questo articolo proponiamo una nostra visione sul futuro della medicina. Presentiamo un discorso che racchiude alcune parole chiave: ricerca, etica, prevenzione, donna

Il futuro della medicina

In questo articolo proponiamo una nostra visione sul futuro della medicina. Presentiamo un discorso che racchiude alcune parole chiave: ricerca, etica, prevenzione, donna

Enhancing the rational use of new medicines across European health care systems

n/

Switching among biosimilars : a review of clinical evidence

Biological medicines have improved patients' outcomes, but their high costs may limit access. Biosimilars, alternatives which have demonstrated high similarity in terms of quality, safety and efficacy to an already licensed originator biological product, could increase competition and decrease prices. Given the expanding number of biosimilars, patients may switch from originator to biosimilar or among biosimilars. Randomized trials and observational studies conducted with multiple biosimilars over many disease areas confirmed the safety and efficacy of switching from originator to biosimilar. This study summarizes evidence on switching between biosimilars for which there are concerns to provide future guidance. Systematic search (Medline, Embase, Cochrane Library) for studies on anti-TNF agents, assessing clinical efficacy and safety of biosimilar-to-biosimilar switch in chronic inflammatory diseases. We retrieved 320 records and included 19 clinical studies. One study with historical control compared switching between biosimilars to maintenance of the same biosimilar. Ten were controlled cohort studies comparing switching between two biosimilars vs switching from originator to a biosimilar or vs multiple switches. Eight were single-arm cohort studies, where participants switched from one biosimilar to another and the outcomes were compared before and after the switch. Overall, these studies did not highlight significant concerns in switching between biosimilars. Therefore, switching studies seem difficult to perform and unnecessary with the body of evidence suggesting no real problems in practice coupled with stringent regulatory requirements. Monitoring the use of biosimilars in clinical practice could support clinical decision making, rational use of biologic medicines, and help to further realize possible savings